NCT01878396 (CMCBRAF) is a clinical trial of Anti-B-RAF in Metastatic Melanoma, sponsored by Istituto Oncologico Veneto IRCCS.

Who is sponsoring NCT01878396?

NCT01878396 is sponsored by Istituto Oncologico Veneto IRCCS.

What drugs are being tested in NCT01878396?

Interventions in NCT01878396: Anti-B-RAF.

What condition does NCT01878396 study?

NCT01878396 studies Metastatic Melanoma.

Is NCT01878396 still recruiting?

NCT01878396 is currently status unknown. Last updated 30 September 2016.

Last reviewed 2016-09-30 · How we verify

NCT01878396: CMCBRAF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF

Status unknown Last updated 30 September 2016

What this trial tests

trial testing Anti-B-RAF in Metastatic Melanoma in 200 participants. Status unknown.

Timeline

1 December 2011

Primary endpoint
1 December 2016

1 December 2017

Quick facts

Lead sponsor	Istituto Oncologico Veneto IRCCS
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 December 2011
Primary completion	1 December 2016
Estimated completion	1 December 2017
Sites	1 location across Italy

Drugs / interventions tested

Anti-B-RAF — full drug profile →

Conditions studied

Metastatic Melanoma — all drugs for Metastatic Melanoma →

Sponsor

Istituto Oncologico Veneto IRCCS — full company profile →

Who can join

18 and older, any sex, with Metastatic Melanoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change of CMC count during treatment and comparison with CT and PET
Time frame: 24 months

Sponsor's own description

The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated BRAF.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response.
Valenti F, Falcone I, Ungania S, Desiderio F, et al · · 2021 · cited 32× · PMID 33917181 · DOI 10.3390/ijms22083837
Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.
Kamińska P, Buszka K, Zabel M, Nowicki M, et al · · 2021 · cited 23× · PMID 34575876 · DOI 10.3390/ijms22189714

Verify or expand the search:

Other recruiting trials for Metastatic Melanoma

Currently open trials in the same condition.

NCT06066138 — A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing · Phase 1 · recruiting
NCT07237100 — Mirdametinib in Patients With Advanced NF1-mutant Melanoma · Phase 2 · recruiting
NCT07086105 — A Study to Evaluate Adze1.C in Participants With Metastatic Melanoma · Phase 1 · recruiting
NCT07112170 — Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma · NA · recruiting
NCT06488365 — In Vivo Liquid Biopsy of Melanoma (Cytophone) · NA · recruiting

Other Istituto Oncologico Veneto IRCCS trials

Trials by the same sponsor.

NCT07185568 — IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumor · NA · not yet recruiting
NCT07338292 — VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures · NA · recruiting
NCT06753136 — Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo · NA · recruiting
NCT06595498 — Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer · NA · active not recruiting
NCT06600568 — Novel Therapeutic Approach for Human T-cell Malignancies · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01878396 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Istituto Oncologico Veneto IRCCS
Last refreshed: 30 September 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01878396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing